| Literature DB >> 16621200 |
Eduardo Martins Netto1, Denise Takahashi, Maria de Fátima Paim de Oliveira, Paulo Barbosa, Neide Ferraz, Ariene Paixão, Luiza Keiko Oyafuso, Cecília Bortoletto, Denise Matos, Maurício Paixão, Anete Olivieri Pessoa da Silva, Roberto Badaro.
Abstract
The treatment effect against psoriasis of an antigen (delipidated, deglycolipidated form of M. vaccae-PVAC) was investigated. One hundred and sixty-five patients were enrolled in three arms (50 or 15 microg or placebo), each receiving a total of two intradermal injections (days 0 and 21). At week 12, a 75% decrease in psoriasis area and severity index was similar among the studied groups (13, 9 and 18%, p=0.429). The overall incidence of adverse events was significantly higher in the PVAC treated groups when compared to placebo (98.2, 87.3 and 70.9%; p<0.001) largely due to local reactions that were limited for the most part to grades 1 and 2 in severity and were self-limiting. Despite its overall safety, PVAC was not clearly indicated to be superior to placebo in the treatment of psoriasis in this study.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16621200 DOI： 10.1016/j.vaccine.2006.03.047
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641